Department of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
J Cell Mol Med. 2024 May;28(10):e18399. doi: 10.1111/jcmm.18399.
Ferroptosis is a distinct mode of cell death, distinguishing itself from typical apoptosis by its reliance on the accumulation of iron ions and lipid peroxides. Cells manifest an imbalance between oxidative stress and antioxidant equilibrium during certain pathological contexts, such as tumours, resulting in oxidative stress. Notably, recent investigations propose that heightened intracellular reactive oxygen species (ROS) due to oxidative stress can heighten cellular susceptibility to ferroptosis inducers or expedite the onset of ferroptosis. Consequently, comprehending role of ROS in the initiation of ferroptosis has significance in elucidating disorders related to oxidative stress. Moreover, an exhaustive exploration into the mechanism and control of ferroptosis might offer novel targets for addressing specific tumour types. Within this context, our review delves into recent fundamental pathways and the molecular foundation of ferroptosis. Four classical ferroptotic molecular pathways are well characterized, namely, glutathione peroxidase 4-centred molecular pathway, nuclear factor erythroid 2-related factor 2 molecular pathway, mitochondrial molecular pathway, and mTOR-dependent autophagy pathway. Furthermore, we seek to elucidate the regulatory contributions enacted by ROS. Additionally, we provide an overview of targeted medications targeting four molecular pathways implicated in ferroptosis and their potential clinical applications. Here, we review the role of ROS and oxidative stress in ferroptosis, and we discuss opportunities to use ferroptosis as a new strategy for cancer therapy and point out the current challenges persisting within the domain of ROS-regulated anticancer drug research and development.
铁死亡是一种独特的细胞死亡方式,通过依赖于铁离子和脂质过氧化物的积累来与典型的细胞凋亡区分开来。在某些病理情况下,如肿瘤,细胞表现出氧化应激和抗氧化平衡之间的失衡,导致氧化应激。值得注意的是,最近的研究表明,由于氧化应激导致的细胞内活性氧 (ROS) 水平升高会增加细胞对铁死亡诱导剂的敏感性或加速铁死亡的发生。因此,理解 ROS 在铁死亡启动中的作用对于阐明与氧化应激相关的疾病具有重要意义。此外,对铁死亡的机制和控制进行全面探索可能为解决特定肿瘤类型提供新的靶点。在这种情况下,我们的综述深入探讨了铁死亡的最新基本途径和分子基础。四个经典的铁死亡分子途径得到了很好的描述,即谷胱甘肽过氧化物酶 4 中心分子途径、核因子红细胞 2 相关因子 2 分子途径、线粒体分子途径和 mTOR 依赖性自噬途径。此外,我们试图阐明 ROS 所发挥的调节作用。此外,我们还概述了针对铁死亡中涉及的四个分子途径的靶向药物及其潜在的临床应用。在这里,我们综述了 ROS 和氧化应激在铁死亡中的作用,并讨论了将铁死亡作为癌症治疗新策略的机会,并指出了 ROS 调节抗癌药物研发中存在的当前挑战。